Pluripotent Stem Cell Purification Using Surface Markers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for differentiating pluripotent stem cells into pancreatic endocrine cells are inefficient and often result in contamination with undifferentiated cells, leading to tumor formation upon transplantation.
Innovation Solution
A multi-step protocol involving culturing pluripotent stem cells through definitive endoderm, primitive gut tube, and pancreatic endoderm lineages to specifically differentiate into pancreatic endocrine cells, using surface markers like CD56, CD133, and CD49c for enrichment and purification, and depleting SSEA4-positive cells to reduce teratoma formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pluripotent stem cells are differentiated into pancreatic endocrine cells using conventional methods, then cell production is achieved, but contamination with undifferentiated cells occurs leading to tumor formation
Solution Approach 1:
The patent segments the differentiation process into distinct stages (definitive endoderm, primitive gut tube, pancreatic endoderm, and pancreatic endocrine cells), with each stage characterized by specific surface markers. This segmentation allows for systematic purification at each transition point, preventing contamination from carrying through to the final product.
Solution Approach 2:
The patent performs preliminary purification actions at each differentiation stage by depleting cells that do not express the appropriate stage-specific surface markers. This preliminary action removes potential tumor-forming cells before they can contaminate the final differentiated population, addressing the reliability issue proactively.
2Manufacturing precision
If surface markers are used for enrichment and purification, then purity of pancreatic endocrine cells is improved, but complexity of the protocol increases
Solution Approach 1:
The patent employs a universal set of surface markers (CD56, CD133, CD49c, SSEA4) that serve multiple functions: they characterize each differentiation stage, enable purification at each stage, and can be used in combination for highly specific enrichment. This multi-functionality reduces the need for separate characterization and purification protocols.
Solution Approach 2:
Surface markers act as intermediaries that bridge the gap between different differentiation stages and enable controlled transitions. By using markers that are sequentially expressed and depleted, the protocol manages complexity through a standardized intermediary system rather than requiring stage-specific custom procedures.
3Productivity
If multi-step differentiation protocol is implemented, then efficiency of forming insulin-producing cells is improved, but time required for differentiation increases
Solution Approach 1:
The patent maintains continuous useful action by ensuring that each differentiation stage seamlessly transitions to the next, with surface marker expression patterns providing continuous guidance. Cells are continuously monitored and purified based on marker expression, preventing backtracking or stagnation, which maintains productivity despite the multi-step nature of the protocol.
Data Source
AI summary
The present invention is directed to methods to differentiate pluripotent stem cells. In particular, the present invention provides methods of characterization of cells differentiated into cells expressing markers characteristic of the pancreatic endocrine lineage utilizing unique surface markers. The present invention also provides methods to enrich or sort cells expressing markers characteristic of the pancreatic endocrine lineage. The present invention also provides methods to deplete cells that may contaminate populations of cells expressing markers characteristic of the pancreatic endocrine lineage formed by the methods of the present invention, thereby reducing the incidence of tumor formation in vivo following transplantation.